Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

PURPOSE: Treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded rapidly. They include the chemotherapies docetaxel and cabazitaxel, hormonal drugs abiraterone and enzalutamide, and best supportive care (BSC). Cabazitaxel has proven to be the last life-prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreis, Kristine, Horenkamp-Sonntag, Dirk, Schneider, Udo, Zeidler, Jan, Glaeske, Gerd, Weissbach, Lothar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160066/
https://www.ncbi.nlm.nih.gov/pubmed/32474839
http://dx.doi.org/10.1007/s41669-020-00219-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160066/
https://www.ncbi.nlm.nih.gov/pubmed/32474839
http://dx.doi.org/10.1007/s41669-020-00219-6

Ejemplares similares